ARR-003 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • ryr3  (Alomone Labs)
    93
    Alomone Labs ryr3
    (A) A genomic map view of <t>Ryr3</t> variants expressed in JSMCs and CSMCs. Three variants TCONS_00167498 (V498, blue), TCONS_00152671 (V671, green), and TCONS_00166589 (V589, red) are indicated by arrows. (B) Expression levels of total Ryr3 in SMCs. (C) Expression levels of each Ryr3 vaiant in SMCs. Variants are arranged on the X-axis from longest (left) to shortest (right) in length. The three variants shown on A are also indicated by the color arrows. (D) A topological map of RYR3 variants. Each circle denotes the corresponding amino acid. Colors on amino acid sequence show distinct regions and domains: red, missing or inserted peptides from differentially spliced exons; green, start codons found in differentially spliced variants. Seven transmembrane domains 1–7 and a pore region (magenta) are shown. MR1-5 (blue), SPRY1-3 (dark green), FKBP1A (orange), CALM (purple), and a residue E (black) that is required for Ca 2+ binding (Ca 2+ ) are also indicated. The topology map was drawn based on the longest peptide variant V498. V671 is a C-terminal truncated variant (V671CT) that is missing Ca 2+ binding and transmembrane domains after the CALM domain while V589 is an N-terminal truncated variant (V589NT) that is missing the N-terminal domains (N-ter to CALM domain). (E) Western blot showing that RYR3 protein expression decreased in jejunum SM of inducible SMC-specific Srf KO mice as SRF protein was depleted 5, 10, 15, and 20 days following tamoxifen administration. UBE1 was used as an endogenous control.
    Ryr3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ryr3/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ryr3 - by Bioz Stars, 2023-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) A genomic map view of Ryr3 variants expressed in JSMCs and CSMCs. Three variants TCONS_00167498 (V498, blue), TCONS_00152671 (V671, green), and TCONS_00166589 (V589, red) are indicated by arrows. (B) Expression levels of total Ryr3 in SMCs. (C) Expression levels of each Ryr3 vaiant in SMCs. Variants are arranged on the X-axis from longest (left) to shortest (right) in length. The three variants shown on A are also indicated by the color arrows. (D) A topological map of RYR3 variants. Each circle denotes the corresponding amino acid. Colors on amino acid sequence show distinct regions and domains: red, missing or inserted peptides from differentially spliced exons; green, start codons found in differentially spliced variants. Seven transmembrane domains 1–7 and a pore region (magenta) are shown. MR1-5 (blue), SPRY1-3 (dark green), FKBP1A (orange), CALM (purple), and a residue E (black) that is required for Ca 2+ binding (Ca 2+ ) are also indicated. The topology map was drawn based on the longest peptide variant V498. V671 is a C-terminal truncated variant (V671CT) that is missing Ca 2+ binding and transmembrane domains after the CALM domain while V589 is an N-terminal truncated variant (V589NT) that is missing the N-terminal domains (N-ter to CALM domain). (E) Western blot showing that RYR3 protein expression decreased in jejunum SM of inducible SMC-specific Srf KO mice as SRF protein was depleted 5, 10, 15, and 20 days following tamoxifen administration. UBE1 was used as an endogenous control.

    Journal: PLoS ONE

    Article Title: Smooth Muscle Cell Genome Browser: Enabling the Identification of Novel Serum Response Factor Target Genes

    doi: 10.1371/journal.pone.0133751

    Figure Lengend Snippet: (A) A genomic map view of Ryr3 variants expressed in JSMCs and CSMCs. Three variants TCONS_00167498 (V498, blue), TCONS_00152671 (V671, green), and TCONS_00166589 (V589, red) are indicated by arrows. (B) Expression levels of total Ryr3 in SMCs. (C) Expression levels of each Ryr3 vaiant in SMCs. Variants are arranged on the X-axis from longest (left) to shortest (right) in length. The three variants shown on A are also indicated by the color arrows. (D) A topological map of RYR3 variants. Each circle denotes the corresponding amino acid. Colors on amino acid sequence show distinct regions and domains: red, missing or inserted peptides from differentially spliced exons; green, start codons found in differentially spliced variants. Seven transmembrane domains 1–7 and a pore region (magenta) are shown. MR1-5 (blue), SPRY1-3 (dark green), FKBP1A (orange), CALM (purple), and a residue E (black) that is required for Ca 2+ binding (Ca 2+ ) are also indicated. The topology map was drawn based on the longest peptide variant V498. V671 is a C-terminal truncated variant (V671CT) that is missing Ca 2+ binding and transmembrane domains after the CALM domain while V589 is an N-terminal truncated variant (V589NT) that is missing the N-terminal domains (N-ter to CALM domain). (E) Western blot showing that RYR3 protein expression decreased in jejunum SM of inducible SMC-specific Srf KO mice as SRF protein was depleted 5, 10, 15, and 20 days following tamoxifen administration. UBE1 was used as an endogenous control.

    Article Snippet: Primary antibodies against the following antigens were used: RYR3 (rabbit, 1:1200, Alomone Labs, Jerusalem, Israel), SRF (rabbit, 1:500, Santa Cruz Biotechnology, Dallas, TX, USA), or GAPDH (mouse, 1:1500, Abcam, Cambridge, MA, USA).

    Techniques: Expressing, Sequencing, Binding Assay, Variant Assay, Western Blot